cemiplimab

CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...

Irving, Texas, USA, August 8, 2026 Caris Life Sciences® announced that the University of New Mexico Comprehensive Cancer Center...

San Diego, California, USA, August 8, 2026 Neurocrine Biosciences, Inc. has initiated a Phase 1 first-in-human clinical study evaluating...

Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...

CHICAGO, July 8, 2026 MAIA Biotechnology announced encouraging interim efficacy results from Part C of its Phase 2 THIO-101...

CHICAGO, June 18, 2026 MAIA Biotechnology, Inc. announced that Winship Cancer Institute of Emory University, Georgia’s only National Cancer...

OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...

TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...